Preview

Колопроктология

Расширенный поиск

ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ТОФАЦИТИНИБА ПРИ ЯЗВЕННОМ КОЛИТЕ (обзор литературы)

https://doi.org/10.33878/2073-7556-2018-0-3-94-102

Полный текст:

Об авторах

М. В. Шапина
ФГБУ «ГНЦК им. А.Н.Рыжих» Минздрава России
Россия


И. Л. Халиф
ФГБУ «ГНЦК им. А.Н.Рыжих» Минздрава России
Россия


Список литературы

1. Ивашкин, В.Т. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. / В.Т.Ивашкин, Ю.А.Шелыгин, И.Л.Халиф и соавт. // Колопроктология. - 2017. - № 1 (59). - с. 6-30.

2. Шапина, М.В. Особенности течения язвенного колита на фоне терапии инфликсимабом / М.В.Шапина, И.Л.Халиф, А.О.Головенко и соавт. // Колопроктология. - 2015. - № 15. - с. 40-43.

3. Neurath, M. Current and emerging therapeutic targets for IBD. / M.Neurath // Nat. Rev. Gastroenterol. Hepatol. - 2017. - № 14. - р. 269-78.

4. Coskun, M. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease / M.Coskun, M.Salem, J.Pedersen et al. // Pharmacol. Res. - 2013. - № 76. - р. 1-8.

5. Flamant, M. Advances in the development of Janus kinase inhibitors in inflammatory bowel disease: future prospects / M.Flamant, J.Rigaill, S.Paul et al. // Drugs. - 2017. - № 77. - р. 1057-68.

6. Danese, S. Filgotinib in Crohn’s disease: JAK is back / S.Danese, G.Fiorino, L.Peyrin-Biroulet. // Gastroenterology. - 2017. - № 153. - р. 603-5.

7. Danese, S. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. / S.Danese, M.Grisham, J.Hodge et al. // Am. J. Physiol. Gastrointest. Liver Physiol. - 2016. - № 310. -G155-G62.

8. Sandborn, W.J. Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis / W.J.Sandborn, S.Ghosh, J.Panes et al. // N. Engl. J. Med. - 2012. - № 367. - р. 616-24.

9. Vanhove, W. Therapeutic innovations in inflammatory bowel diseases. / W.Vanhove, K.Nys, S.Vermeire // Clin. Pharmacol. Ther. - 2016. - № 99. -р. 49-58.

10. Meyer, D.M. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis / D.M.Meyer, M.I.Jesson, X.Li et al. // J. Inflamm. - 2010. № 7 (1). - р. 41.

11. Meyer, D.M. Modulation of innate and adaptive immune modulation of innate and adaptive immune responses by tofacitinib (CP-690,550) / D.M.Meyer, N.Kishore, J.J.O’Shea et al. // J. Immunol. - 2011. -№ 186. - p. 4234-4243.

12. Dowty, M.E. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. / M.E.Dowty, J.Lin, T.F. Ryder et al. // Drug Metab. Dispos. - (2014). -№ 42 (4). - p. 759-773.

13. Sandborn, W.J. Tofacitinib as induction and maintenance therapy for ulcerative colitis / W.J.Sandborn, C.Su, B.E.Sands et al. // N. Engl. J. Med. - 2017. - № 376 (18). - p. 1723-1736.

14. Sandborn, W.J. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis / W.J.Sandborn, S.Ghosh, J.Panes et al. // N. Engl. J. Med. - 2012. -№ 367 (7). - p. 616-624.

15. Sandborn, W.J. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. / W.J.Sandborn, C.Su, B.E.Sands et al. // N. Engl. J. Med. - 2017. - № 376. - p. 1723-36.

16. Shah, S.C. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease / S.C.Shah, J-F Colombel, B.E.Sands et al. // Aliment. Pharmacol. Ther. - 2016. - № 43 (3). - p. 317-333.

17. Peyrin-Biroulet, L. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target / L.Peyrin-Biroulet, W.Sandborn, B.E.Sands et al. // Am. J. Gastroenterol. - 2015. - № 110 (9). - p. 1324-1338.

18. Casellas, F. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. / F.Casellas, M.Barreiro de Acosta, M.Iglesias et al. // Eur. J. Gastroenterol. Hepatol. -2012. - № 24 (7). - p. 762-769

19. Panes, J. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes / J.Panes, C.Su, A.G.Bushmakin et al. // BMC Gastroenterol. - 2015. - № 15 (1). - p. 14.

20. Panes, J. Tofacitinib in patients with ulcerative colitis: health-related quality of life in Phase 3 randomized controlled induction and maintenance studies / J.Panes, S.Vermeire, J.O.Lindsay et al. // J. Crohns Colitis. - 2017. - № 12 (2). - p. 145-156.

21. Panés, J. Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption:Results from the OCTAVE clinical trials / J.Panés, B.Bressler, J.-F.Colombel et al. // ECCO Abstract. - P516 S366-367.

22. Sands, B.E. Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open / B.E.Sands, A.C.Moss, A.Armuzzi et al. // ECCO Abstract. - DOP026 S049

23. Olivera, P. Next generation of small molecules in inflammatory bowel disease / P.Olivera, S.Danese, L.Peyrin-Biroulet. // Gut. - 2017. - №2 66. - p. 199-209.

24. Medscape. FDA approves tofacitinib for rheumatoid arthritis. 2012 http://www.medscape. com/viewarticle/774015.

25. Medscape. Xeljanz approved for rheumatoid arthritis in European Union. 2017. http://www. medscape.com/viewarticle/877865.

26. Olivera, P. JAK inhibition in inflammatory bowel disease / P.Olivera, S.Danese, L.Peyrin-Biroulet // Expert Rev. ClinImmunol. - 2017. - №2 13. - p. 693-703.

27. Ruderman, E.M. Overview of safety of nonbiologic and biologic DMARDs / E.M.Ruderman // Rheumatology (Oxford). - 2012. - № 51 (Suppl 6). -vi 37-43.

28. Curtis, J.R. Real-world comparative risks of herpes virus infections in tofacitiniband biologic-treated patients with rheumatoid arthritis / J.R.Curtis, F.Xie, H.Yun et al. // Ann. Rheum Dis. - 2016. - № 75. -p. 1843-7.

29. Winthrop, K.L. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy / K.L.Winthrop, J.R.Curtis, S.Lindsey et al. // Arthritis Rheumatol. - 2017. - № 69. - p. 1960-8.

30. Harpaz, R. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Preventionof herpes zoster: recommendations of the Advisory Committee on ImmunizationPractices (ACIP) / R.Harpaz, I.R.Ortega-Sanchez, J.F.Seward // MMWR Recomm. Rep. 2008. -№ 57. - p. 1-30.

31. Rubin, L.G. Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host / L.G.Rubin, M.J.Levin, P.Ljungman et al. // Clin. Infect. Dis. -2014. - № 58. - e44-100.

32. Winthrop, K.L. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib, a randomized phase II trial / K.L.Winthrop, A.G.Wouters, E.H.Choy et al. // Arthritis Rheumatol. - 2017. - № 69. -p. 1969-77.

33. Pouillon, L. Tofacitinib is the right OCTAVE for ulcerative colitis / L.Pouillon, P.Bossuyt, L.Peyrin-Biroulet. // Gastroenterology. - 2017. - № 153. -p. 862-4.

34. Cohen, S.B. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials / S.B.Cohen, Y.Tanaka, X.Mariette et al. // Ann Rheum Dis. - 2017. - № 76. - р. 1253-1262.

35. Cosnes, J. Epidemiology and natural history of inflammatory bowel diseases / J.Cosnes, C.Gower-Rousseau, P.Seksik et al. // Gastroenterology. - 2011. - № 140. - p. 1785-94.

36. Pfizer Inc. Xeljanz prescribing information. 2014 http://labeling.pfizer.com/ShowLabeling. aspx?id=959.

37. Clowse, M.E. Pregnancy outcomes in the tofacitinibsafety databases for rheumatoid arthritis and psoriasis / M.E.Clowse, S.R.Feldman, J.D.Isaacs et al. // Drug. Saf. - 2016. - № 39. - p. 755-62.

38. Curtis, J.R. Efficacy and safety of tofacitinibin older and younger patients with rheumatoid arthritis / J.R.Curtis, H.Schulze-Koops, L.Takiya et al. // Clin. Exp. Rheumatol. - 2017. - № 35. - p. 390-400.

39. Pfizer. An open-label multiple dose study to evaluate the pharmacokinetics, safety and tolerability of CP-690,550 in pediatric patients from 2 to less than 18 years of age with juvenile idiopathic arthritis. 2017 https://clinicaltrials.gov/show/NCT01513902. -Accessed August 30. - 2017.

40. Dowty, M.E. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans / M.E.Dowty, J.Lin, T.F.Ryder et al. // Drug. Metab. Dispos. - 2014. -№ 42. - p. 759-73.

41. Harbord, M. European Crohn’s and Colitis Organisation. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management / M.Harbord, R.Eliakim, D.Bettenworth et al. // J. Crohns Colitis. -2017. - № 11. - p. 769-84.

42. Rubin, D.T. Comparative efficacy and safety of tofacitinib and biologics as induction therapy for moderately-to-severely active ulcerative colitis: a systematic review and network meta-analysis / D.T.Rubin, A.O.Ashaye, Y.Zhang et al. // Presented at: 25th United European Gastroenterology Week. Barcelona, Spain, 28 October. - 2017. - № 1.

43. Sandborn, W.J. Tofacitinib as induction and maintenance therapy for ulcerative colitis / W.J.Sandborn, C.Su, B.E.Sands et al. // N. Engl. J. Med. - 2017. - № 376 (18). - p. 1723-1736.


Для цитирования:


Шапина М.В., Халиф И.Л. ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ТОФАЦИТИНИБА ПРИ ЯЗВЕННОМ КОЛИТЕ (обзор литературы). Колопроктология. 2018;(3):94-102. https://doi.org/10.33878/2073-7556-2018-0-3-94-102

For citation:


Khalif I.L., Shapina M.V. EFFICACY AND SAFETY OF TOFACITINIB IN ULCERATIVE COLITIS (review). Koloproktologia. 2018;(3):94-102. (In Russ.) https://doi.org/10.33878/2073-7556-2018-0-3-94-102

Просмотров: 287


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-7556 (Print)
ISSN 2686-7303 (Online)